| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/28/2002 | US20020037854 Use of at least one no synthase inhibitor for treating sensitive skin |
| 03/28/2002 | US20020037852 Anticarcinogenic agents |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037843 Method and composition for modulating amyloidosis |
| 03/28/2002 | US20020037839 Antiischemic agents; hypotensive agents; antiiflammatory agents |
| 03/28/2002 | US20020037837 Microcapsules; active materials, water in oil emulsion |
| 03/28/2002 | US20020037831 1-Nitroacridine/tumor inhibitor compositions |
| 03/28/2002 | US20020037830 Adjust glycogen concentration |
| 03/28/2002 | US20020037829 Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| 03/28/2002 | US20020037828 Pretreatment sexual intercourse |
| 03/28/2002 | US20020037578 Inhibiting homoserine lactone (HSL) and/or acylated homoserine lactone (AHL) regulated processes in microorganisms, such as swarming or swimming with a furanone compound; use on pathogens of plants, fish, animals, and crustaceans |
| 03/28/2002 | US20020037574 Recombinant C-proteinase and processes, methods and uses thereof |
| 03/28/2002 | US20020037572 Novel mammalian secreted group III phospholipase A2 |
| 03/28/2002 | US20020037561 Method for producing arachidonic acid |
| 03/28/2002 | US20020037538 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| 03/28/2002 | US20020037533 A compound that is a Prolactin Releasing Peptide receptor (PrRP) agonist; determining the ability of the compound to promote wakefulness; providing a PrRP receptor antagonist and determining the ability of the compound to promote sleep |
| 03/28/2002 | US20020037501 Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome |
| 03/28/2002 | US20020037491 Oral transmucosal delivery |
| 03/28/2002 | US20020037333 For therapy of hepatic disorders caused by the failure of immune system |
| 03/28/2002 | US20020037329 Biochemically balanced peritoneal dialysis solutions |
| 03/28/2002 | US20020037328 Hexitol compositions and uses thereof |
| 03/28/2002 | US20020037327 Dissociating covalent bonds in an ozonide lesion in an oncogene's TATA box for cancer therapy |
| 03/28/2002 | US20020037324 Aqueous solubility pharmaceutical formulations |
| 03/28/2002 | US20020037322 Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof |
| 03/28/2002 | US20020037314 For therapy of rosacea or other inflammatory skin affliction, cosmetics |
| 03/28/2002 | US20020037313 Sustained-release nalmefene preparations and method |
| 03/28/2002 | US20020037312 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 03/28/2002 | US20020037311 Transdermal delivery of lasofoxifene |
| 03/28/2002 | US20020037305 Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders |
| 03/28/2002 | US20020037299 Cosmetic compositions comprising zinc salts of piroctone olamine |
| 03/28/2002 | US20020037298 Cosmetic compositions containing inorganic-organic hybrid prepolymers and methods of treating hair, skin or nails using same |
| 03/28/2002 | US20020037297 For therapy and prophylaxis allergic rhinitis, vasomotoric rhinitis, conjunctivitis, cold, and flu |
| 03/28/2002 | US20020037296 For therapy and diagnosis of the human or animal body, anti-tumour prodrugs and those which are specifically activated by the hydroxylation activity of the P- 450 enzyme CYP1B1 |
| 03/28/2002 | US20020037293 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 03/28/2002 | US20020037291 Sphingoglycolipid |
| 03/28/2002 | US20020037276 Culturing a mammalian endocrine precursor cell in the presence of a phosphatidylinositol 3-kinase (PI3K) inhibitor whereby endocrine precursor cell differentiates into a cell having endocrine activity |
| 03/28/2002 | US20020037268 Antimicrobial sanitizing lotion with skin protection properties |
| 03/28/2002 | US20020037265 Preparation for breast duct fluid collection |
| 03/28/2002 | US20020037260 Compositions for treating biofilm |
| 03/28/2002 | US20020037257 Crystalline; substantially smooth and having a BET value from 1 to 4.5 m2/g; treatment of respiratory disorders by administration |
| 03/28/2002 | US20020035996 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 03/28/2002 | US20020035993 Highly efficient delivery of a large therapeutic mass aerosol |
| 03/28/2002 | DE10139115A1 Citalopram enthaltende pharmazeutische Zusammensetzung Citalopram pharmaceutical composition containing |
| 03/28/2002 | DE10046541A1 Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix |
| 03/28/2002 | DE10046272A1 New biphenyl-substituted amino-(iso)quinoline derivatives, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, angina pectoris or restenosis |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/28/2002 | DE10043282A1 Medicaments containing amyloid-beta-protein formation and/or secretion inhibitors, are used for treating hypertension, diabetes, arteriosclerosis, rheumatism, cardiac infarction, inflammation or sepsis |
| 03/28/2002 | DE10042625A1 Deodorizing apparatus for sewage line, has deodorizing tower with deodorizing layer, catalytic reaction tower with catalyst for reacting catalyst with deodorized gas to form odorless gas |
| 03/28/2002 | DE10042412A1 Transdermal patch for administering venlafaxin, useful for prophylaxis or therapy of psychoses, especially depression, as well as anxiety, neuroses and psychopathies |
| 03/28/2002 | CA2824077A1 Oral preparations with favorable disintegration characteristics |
| 03/28/2002 | CA2433157A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | CA2424576A1 Efficient process for the preparation of a factor xa inhibitor |
| 03/28/2002 | CA2423356A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | CA2423334A1 Prodrugs of a 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotic |
| 03/28/2002 | CA2423329A1 Solid preparations |
| 03/28/2002 | CA2423315A1 Substituted amino-aza-cycloalkanes useful against malaria |
| 03/28/2002 | CA2423284A1 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 03/28/2002 | CA2423262A1 Resorcinol derivatives |
| 03/28/2002 | CA2423172A1 Sustained release composition containing clarithromycin |
| 03/28/2002 | CA2423170A1 Pharmaceutical semi-solid composition of isotretinoin |
| 03/28/2002 | CA2423156A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | CA2423154A1 Imidazole derivatives as raf kinase inhibitors |
| 03/28/2002 | CA2423151A1 Indole derivatives and their use as antifungal and/or antiparasitic agents |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423095A1 The use of melatonin for induction of general anesthesia |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423050A1 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | CA2423044A1 Induction of exon skipping in eukaryotic cells |
| 03/28/2002 | CA2422991A1 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| 03/28/2002 | CA2422983A1 Methods for treating various eye disorders |
| 03/28/2002 | CA2422964A1 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | CA2422923A1 Pyridine derivatives with ikb-kinase (ikk-.beta.) inhibiting activity |
| 03/28/2002 | CA2422820A1 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | CA2422686A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | CA2422671A1 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | CA2422625A1 Method for use of igf-binding protein for selective sensitization of target cells in vivo |
| 03/28/2002 | CA2422568A1 Prognostic indicator |
| 03/28/2002 | CA2422560A1 4-amino-quinazolines |
| 03/28/2002 | CA2422544A1 Conditionally replicating viral vectors and their use |
| 03/28/2002 | CA2422535A1 Treatment of diseases with adamantane derivatives |
| 03/28/2002 | CA2422527A1 Treatment of tinnitus |
| 03/28/2002 | CA2422488A1 4-amino-quinazolines |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421869A1 Tetrahydrofuran derivatives and their use as nk-1 antagonists |
| 03/28/2002 | CA2421823A1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | CA2421485A1 Water soluble rapamycin esters |
| 03/28/2002 | CA2420210A1 Stereoselective process for preparing cyclohexyl amine derivatives |
| 03/28/2002 | CA2420185A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | CA2418208A1 Compounds having fungicidal activity and processeses to make and use same |
| 03/28/2002 | CA2416136A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/28/2002 | CA2407465A1 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
| 03/28/2002 | CA2357901A1 Combination treatment for depression and anxiety |
| 03/28/2002 | CA2357853A1 Use of growth hormone secretagogues in conjunction with physical exercise |
| 03/27/2002 | EP1191611A2 Piezoelectric element and process for production thereof |
| 03/27/2002 | EP1191099A1 Novel polypeptide and dna thereof |
| 03/27/2002 | EP1191097A1 Induction of exon skipping in eukaryotic cells |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1191035A2 Three members of the cytokin-receptor class II family |
| 03/27/2002 | EP1191027A1 Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists |
| 03/27/2002 | EP1191026A1 New pyridazine endothelin antagonists |